Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Thyroid Gland Disorder Treatment Market

Thyroid Gland Disorder Treatment Market Trends

Report ID: GMI4214
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Thyroid Gland Disorder Treatment Market Trends

Rising healthcare expenditure globally reflects a growing investment in the diagnosis, treatment, and management of thyroid disorders. Governments, healthcare organizations, and insurance providers allocate significant resources to address the healthcare needs of individuals with thyroid disorders.

Increased healthcare spending supports the development and adoption of innovative treatments, including novel drug delivery systems, advanced diagnostic technologies, and precision medicine approaches. This investment fosters innovation and drives market growth by expanding access to innovative therapies and improving patient outcomes.
Furthermore, expanding healthcare coverage and reimbursement policies ensure that patients have access to essential thyroid disorder treatments, reducing financial barriers to care and further propelling the market growth.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Thyroid gland disorder treatment market size was USD 2.4 billion in 2023 and is expected to reach over USD 3.3 billion by 2032 owing to the technological advancements like improved pharmaceutical drug delivery worldwide.

The levothyroxine segment is expected to record USD 1.6 billion by 2032 due to serving as the first-line therapy due to its effectiveness, affordability, and accessibility.

North America thyroid gland disorder treatment industry held 40.7% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to presence of highly developed healthcare infrastructure with state-of-the-art facilities and advanced medical technologies in the region.

AbbVie Inc., Aspen Pharmacare Holdings Limited, Glenmark Pharmaceuticals Ltd., Lannett Company, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited, are some of the major thyroid gland disorder treatment companies worldwide.